Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Growth ETF (NY:JGRO)

96.74 +0.30 (+0.31%)
Streaming Delayed Price Updated: 11:33 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Growth ETF

< Previous 1 2 Next >
McDonald’s Stock Edges Higher After Citigroup Boosts Price Target
Citigroup said that it views McDonald's value price initiatives, easy comparisons, and potential for multiple expansion as reasons to own the stock. 
Via Stocktwits
Amazon Stock Received A Price Target Hike From Truist – Here’s Why
Via Stocktwits
Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened
Via Stocktwits
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside
Via Stocktwits
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report
Via Stocktwits
US FTC Probes Amazon, Google Over Search Advertising Practices: Report
Via Stocktwits
AbbVie Stock Touches Record High After Company Dismisses Generic Competition For Rinvoq Till 2037: Wells Fargo Terms It A ‘Big Win’
Via Stocktwits
GE Vernova To Sell Proficy Software Unit To TPG For $600M
Via Stocktwits
This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?
Via Stocktwits
Apple Plans Tabletop Robot, Among Other AI Products, Says Report
Via Stocktwits
Topics Artificial Intelligence
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday. 
Via Stocktwits
Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies
The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated. 
Via Stocktwits
Topics Artificial Intelligence
Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720
According to the Financial Times, the price for a month’s supply of the highest doses of the drug will rise from £122 to £330, an increase of 170%. 
Via Stocktwits
Topics Government World Trade
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant
Via Stocktwits
US Regulator Grants Exemption For Zoox Vehicles To Be On Road Without Compliance With Federal Standards
Via Stocktwits
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance
Texas Attorney General Ken Pax­ton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs. 
Via Stocktwits
Topics Fraud Law Enforcement Lawsuit
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive
The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting... 
Via Stocktwits
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet
Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday. 
Via Stocktwits
Topics Workforce
Abbott Stock Slips On Disappointing Q3 Earnings Forecast: Retail Chatter Rises Over 200% In 24 Hours
Abbott’s sales of continuous glucose monitors were $1.9 billion in the second quarter, marking a growth of 21.4% on a reported basis, the company said. 
Via Stocktwits
Topics Artificial Intelligence
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. 
Via Stocktwits
Topics Product Recall
Intuitive Surgical Gets FDA Clearance For Advanced Energy Surgical Instrument: Retail Sentiment Improves
Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument designed to seal, cut, grasp, and dissect tissue for use with Intuitive’s da Vinci surgical systems. 
Via Stocktwits
Crumly Loads Up on 110,675 SDVY Shares in Q2 Filing
Crumly & Associates Inc. reported purchasing 110,675 shares of SDVY valued at $3.81 million in Q2 2025, according to a July 2 SEC filing. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries
Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three years in countries supported by the Global Fund, at no profit to the company. 
Via Stocktwits
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less... 
Via Stocktwits
Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta
J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April. 
Via Stocktwits
Topics Government
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade
The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases. 
Via Stocktwits
Topics Intellectual Property
Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care
Jefferies termed the Supreme Court’s ruling an ‘incremental positive’ for Gilead that removes an overhang going into the launch for Yeztugo. 
Via Stocktwits
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.